LSV Asset Management Reduces Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

LSV Asset Management lowered its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 18.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 777,124 shares of the biopharmaceutical company's stock after selling 174,200 shares during the quarter. LSV Asset Management owned about 0.65% of Catalyst Pharmaceuticals worth $16,219,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $27,000. Farther Finance Advisors LLC raised its stake in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after purchasing an additional 1,495 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at $65,000. KBC Group NV lifted its position in Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after purchasing an additional 1,542 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth about $134,000. 79.22% of the stock is owned by institutional investors.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now owns 188,564 shares of the company's stock, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now directly owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company's stock.

Remove Ads

Catalyst Pharmaceuticals Stock Up 1.9 %

Shares of CPRX stock traded up $0.43 on Tuesday, hitting $23.23. The stock had a trading volume of 932,770 shares, compared to its average volume of 1,141,772. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $26.16. The business has a 50 day moving average price of $22.62 and a 200 day moving average price of $22.05. The company has a market cap of $2.82 billion, a PE ratio of 19.69, a P/E/G ratio of 3.31 and a beta of 0.79.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. Finally, Stephens reiterated an "overweight" rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.